---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-223743"
form_type: "8-K"
ticker: "DBVT"
cik: "0001613780"
company_name: "DBV Technologies S.A."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:26:55.460661+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DBV completes VITESSE Phase 3 screening early; topline data expected Q4 2025

## Summary
- Screening closed in August 2024, ahead of schedule; enrollment exceeded original goal.
- VITESSE enrolled >600 peanut-allergic children ages 4-7 across 86 sites in U.S., Canada, Europe, UK, Australia.
- Subjects randomized 2:1 to active Viaskin Peanut Patch vs placebo; 12-month study.
- Largest immunotherapy trial in peanut allergy; DBV targets Biologic License Application submission after data.
- Topline efficacy and safety results from VITESSE expected by Q4 2025.

## SEC filing metadata
- accession: 0001193125-24-223743
- form_type: 8-K
- ticker: DBVT
- cik: 0001613780
- company_name: DBV Technologies S.A.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613780/000119312524223743/0001193125-24-223743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613780/000119312524223743/d837908d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-223743
- JSON: https://secwatch.observer/filing/0001193125-24-223743.json
- Plain text: https://secwatch.observer/filing/0001193125-24-223743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.